This study, which was presented during the 2018 Gastrointestinal Cancers Symposium, included 3 patients with pancreatic cancer—2 with TPR-NTRK gene fusion and 1 with an SCL-ROS1 gene fusion. These patients were given entrectinib at 600 mg daily, which has shown substantial clinical activity in patients with advanced or metastatic solid tumors that harbor these fusions. Read more . . .
In a study of patients with metastatic pancreatic cancer who harbor NTRK and ROS1 fusions, investigators evaluated the selective TRK and ROS1 inhibitor entrectinib, which is both potent and active in patients with CNS metastases, where results showed early signs of antitumor activity.